Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's disease

This page shows the latest Alzheimer's disease news and features for those working in and with pharma, biotech and healthcare.

Theranexus takes Alzheimers drug combo into clinic

Theranexus takes Alzheimer’s drug combo into clinic

Theranexus has been the green light to start trials of an Alzheimer’s disease therapy (AD) based on two generic medicines by the French authorities. ... Improving the management of neurocognitive disorders, particularly in Alzheimer's disease, remains

Latest news

More from news
Approximately 52 fully matching, plus 330 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which are both at preclinical stage for Alzheimer's disease, ... for local administration for the

  • Pfizer and IBM's tech-enabled 'Parkinson’s house' Pfizer and IBM's tech-enabled 'Parkinson’s house'

    But this elegant home, surrounded by manicured lawns, is wired to beat the scourge of Parkinson’s disease. ... Since this article was written Pfizer has substantially scaled back its neuroscience R&D work into conditions such as Parkinson's and

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimers advances

    All we really know is that evidence of amyloid deposition begins up to maybe 20 years before the onset of Alzheimer’s disease. ... Of course, the possibility remains that neither tau nor amyloid are responsible for the development of Alzheimer’s

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    The in-partnering deals included the $1bn deal with Bicycle Therapeutics and the Alzheimer's collaboration with Lilly. ... development agreement with AstraZeneca for a phase I antibody selective for amyloid-beta 42 in Alzheimer's disease.

  • Behavioural science in 2030 Behavioural science in 2030

    And I posit that this should be addressed through a further evolution of the novel adaptive licensing strategies currently being trialled in Alzheimer's disease and breast cancer. ... has brought us ever closer to exquisite precision in disease diagnosis

More from intelligence
Approximately 1 fully matching, plus 23 partially matching documents found.

Latest appointments

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Alzheimer's disease. ... His outstanding track record and expertise in neurodegenerative disease are crucial as we are about to progress our first highly brain penetrant and orally bioavailable tau modifier into the clinic for

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... s disease, where we are working to

  • Chase adds former Allergan execs to leadership team Chase adds former Allergan execs to leadership team

    With its robust intellectual property, pharmaceutical assets and elegant development strategy, Chase has the opportunity to profoundly reshape the approach to the symptomatic treatment of Alzheimer's disease. “ ... disease.”. 20th June 2016.

  • Eisai recruits Pfizer and Sanofi execs to neurology group Eisai recruits Pfizer and Sanofi execs to neurology group

    Eisai has also appointed Beyhan Zaim to its US Neurology Business Group as VP, commercial development and Alzheimer's Disease global lead. ... As global lead for Alzheimer's Disease she will also be tasked with developing strategies and heading internal

More from appointments
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest from PMHub

  • The dark side of direct-to-consumer genetic tests

    Instead, they interpret single-nucleotide polymorphisms (SNPs), and while SNPs can indicate a gene is associated with a disease, many are benign and have no impact on health. ... Who can blame them? If an email landed in your inbox that appeared to

  • Alzheimers disease: reviewing the immediate treatment horizon

    Alzheimer’ s disease: reviewing the immediate treatment horizon. Account Manager Stuart Goodman takes a look at some of the promising categories of Phase 3 treatments that could soon be available to ... A recent article by BLH Consultant David Cooney

  • Alzheimer's: the numbers we cannot forget

    I would love to be talking about our latest thinking around launching new therapies in Alzheimer’ s disease (AD) but I can’ t – no one can. ... Among the worst attrition rates in the industry. 99.6% of all trials in Alzheimer’ s disease (AD)

  • Atlantis Healthcare

    We have delivered over 130 international support programmes across 90+ disease states including, among others: Alzheimer’s disease. ... It’s enlightening to see such an innovative support programme aimed at tackling some of the fundamental issues in

  • PharmiWeb Solutions

    Some of the world's largest pharmaceutical companies choose us for mission critical digital programmes. ... difference. A new and innovative drink for the dietary management of early Alzheimer’ s disease.

More from PMHub
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics